Loading organizations...

§ Private Profile · Cambridge, MA, USA
hC Bioscience is a technology company.
hC Bioscience develops first-in-class tRNA-based therapeutics for protein dysfunction in genetically defined diseases. Its precision protein editing platform uses anticodon engineered tRNAs to overwrite premature termination codons, causing non-functional proteins. This innovative approach restores protein function without altering genetic material, offering a reversible strategy for diseases, independent of gene or mutation.
Leslie Williams founded hC Bioscience in 2021, driven by the insight that tRNA-based protein editing could functionally reverse disease-causing nonsense mutations. As founding CEO, President, and Director, Williams established a novel, gene-agnostic method for restoring protein function, leveraging advanced tRNA biology to build a versatile platform for precise therapeutic interventions.
The company targets patients with genetically defined conditions, including rare diseases and certain cancers. Its lead program focuses on severe hemophilia A, demonstrating ability to restore full-length Factor VIII protein. hC Bioscience envisions its platform applicable to liver-based disorders, Duchenne muscular dystrophy, and related conditions, aspiring to improve patient lives by correcting protein deficiencies.
hC Bioscience has raised $40.0M across 2 funding rounds.
hC Bioscience has raised $40.0M in total across 2 funding rounds.
hC Bioscience has raised $40.0M across 2 funding rounds. Most recently, it raised $16.0M Series A Extension in November 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 4, 2022 | $16M Series A Plus | — | 8VC, ARCH Venture Partners, Seiji Miyahara, Takeda Ventures | Announced |
| Feb 1, 2022 | $24M Series A | — | 5AM Ventures, 8VC, Dave Maki, ARCH Venture Partners, Atlas Venture, Polaris Partners | Announced |
hC Bioscience is a Cambridge, MA–based biotechnology company developing first‑in‑class, tRNA‑based “protein editing” therapeutics that aim to restore functional proteins by overwriting disease‑causing mutations rather than altering DNA or mRNA directly[1][4].
High‑Level Overview
For the company specifically:
Origin Story
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
Quick take: hC Bioscience is an early, well‑capitalized (venture‑backed) biotech attempting to create a new therapeutic class—anticodon‑engineered tRNA protein editing—with advancing preclinical data and a clear path toward IND and human studies; success would broaden the toolkit for genetic disease treatment and reshape parts of RNA therapeutics and rare disease strategy[3][4][2].
(If you’d like, I can produce a one‑page investor‑style brief with milestones, risks, and key open questions for due diligence.)
hC Bioscience has raised $40.0M in total across 2 funding rounds.
hC Bioscience's investors include 8VC, ARCH Venture Partners, Seiji Miyahara, Takeda Ventures, 5AM Ventures, Dave Maki, Atlas Venture, Polaris Partners.